<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: <z:chebi fb="0" ids="601027">Aliskiren</z:chebi> is the first in a new class of orally active direct renin inhibitors, approved for the treatment of <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the efficacy of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> in diabetic cardiovascular complications remains to be defined </plain></SENT>
<SENT sid="2" pm="."><plain>This study aimed to test the hypothesis that <z:chebi fb="0" ids="601027">aliskiren</z:chebi> may enhance the beneficial effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> against cardiovascular injury associated with diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> was induced in rats by unilateral nephrectomy followed by <z:chebi fb="1" ids="9288">streptozotocin</z:chebi> injection </plain></SENT>
<SENT sid="4" pm="."><plain>Diabetic nephropathic rats were orally given vehicle, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, <z:chebi fb="0" ids="601027">aliskiren</z:chebi>, or combined <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and <z:chebi fb="0" ids="601027">aliskiren</z:chebi> for four weeks to compare their effects on cardiovascular injury, particularly <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>KEY FINDINGS: <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> treatment significantly attenuated cardiac <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation, oxidative injury and <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> in diabetic nephropathic rats </plain></SENT>
<SENT sid="6" pm="."><plain>This was associated with up-regulation of transforming growth factor-Î²1 and matrix metalloproteinase-2 genes, along with down-regulation of tissue inhibitor of metalloproteinase-2 gene in cardiac tissue </plain></SENT>
<SENT sid="7" pm="."><plain>The combination of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> exerted greater beneficial effect than monotherapy with either drug, on <z:hpo ids='HP_0000001'>all</z:hpo> the aforementioned parameters </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Our findings suggested that <z:chebi fb="0" ids="601027">aliskiren</z:chebi> enhanced the protective effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> against <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo>, in experimental diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, the combination of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> may be a potential therapeutic strategy for cardiovascular injury associated with diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>